Home » Stocks » EVLO

Evelo Biosciences, Inc. (EVLO)

Stock Price: $9.54 USD 0.11 (1.17%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 509.19M
Revenue (ttm) n/a
Net Income (ttm) -98.82M
Shares Out 53.37M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $9.54
Previous Close $9.43
Change ($) 0.11
Change (%) 1.17%
Day's Open 9.55
Day's Range 9.19 - 9.80
Day's Volume 163,948
52-Week Range 3.55 - 19.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief Fina...

1 week ago - GlobeNewsWire

–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting–

2 weeks ago - GlobeNewsWire

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying...

Other stocks mentioned: IKNA, ATNF
3 weeks ago - Benzinga

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that...

1 month ago - GlobeNewsWire

-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select...

1 month ago - GlobeNewsWire

–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expec...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, FHTX, KLDO, MCRB, MRNA ...
2 months ago - PRNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

Other stocks mentioned: HOG, TXN, ADS, BDGE, BRO, MSM, OTLK ...
3 months ago - Benzinga

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, toda...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, toda...

3 months ago - GlobeNewsWire

–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured  physician-reported outcomes –

3 months ago - GlobeNewsWire

-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial to 2Q...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which a...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in th...

5 months ago - GlobeNewsWire

Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition.

5 months ago - Seeking Alpha

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months ---...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, ...

6 months ago - GlobeNewsWire

–Data expected in 1Q 2021– –Data expected in 1Q 2021–

6 months ago - GlobeNewsWire

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting bi...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting bi...

8 months ago - GlobeNewsWire

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in mod...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting bio...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically...

10 months ago - GlobeNewsWire

—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust— —Experimental therapies with potential to prevent and treat complications of COVID-19— —EDP1815 selected as ...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting bio...

10 months ago - GlobeNewsWire

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

Evelo Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

11 months ago - Zacks Investment Research

Evelo Biosciences Inc (EVLO) CEO Simba Gill on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020––Selected enteric capsule formulation of EDP1815 for Phase 2 dose ...

11 months ago - GlobeNewsWire

—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial— —Dat...

1 year ago - GlobeNewsWire

Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex Industry veteran brings deep experience in drug development from leadership roles at Regeneron a...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting bi...

1 year ago - GlobeNewsWire

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 -- CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology co...

1 year ago - GlobeNewsWire

Industry veteran brings expertise in manufacturing, R&D, and operations from leadership roles at Novartis, Eli Lilly, and Moderna Industry veteran brings expertise in manufacturing, R&D, and operations ...

1 year ago - GlobeNewsWire

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Evelo Biosciences (EVLO) CEO Simba Gill on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About EVLO

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2018
Stock Exchange
NASDAQ
Ticker Symbol
EVLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for EVLO stock is "Buy." The 12-month stock price forecast is 21.40, which is an increase of 124.32% from the latest price.

Price Target
$21.40
(124.32% upside)
Analyst Consensus: Buy